About the Journal

Chinese Clinical Oncology

The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.

The entire submission and review process are managed through OJS system, an electronic system, which provides an efficient way and ensures a rapid turnaround of papers submitted for publication. See more at  Author Instruction.

Average Submission Turnaround Time:
         Submission to First Editorial Decision: 3-5 days.
         Acceptance to Publication Ahead of Print: 20 days.
         Acceptance to Publication: 1-3 months. Original Articles are listed as priority.

The Official Publication of: 
         Society for Translational Medicine (STM), Hong Kong
         Endorsed by Chinese Society of Clinical Oncology (CSCO).

AME Publishing Company
Address: Rm C, 16/F, Kings Wing Plaza 1, No. 3 On Kwan Street, Shatin, NT, Hong Kong
Phone: +86 20 66355775
Email: editor@thecco.net